A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
The global Monoclonal antibodies (mAbs) Biosimilars market was valued at US$ 4677.5 million in 2023 and is anticipated to reach US$ 5307 million by 2030, witnessing a CAGR of 1.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Monoclonal antibodies (mAbs) Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal antibodies (mAbs) Biosimilars.
Report Scope
The Monoclonal antibodies (mAbs) Biosimilars market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Monoclonal antibodies (mAbs) Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Monoclonal antibodies (mAbs) Biosimilars companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
Segment by Type
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others
Segment by Application
Anti-Cancer
Anti-Inflammatory/Autoimmune
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Monoclonal antibodies (mAbs) Biosimilars companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Erythropoietin (EPO)
1.2.3 Human Growth Hormone (HGH)
1.2.4 Granulocyte- Colony Stimulating Factor (G-CSF)
1.2.5 Monoclonal Antibody (mAb)
1.2.6 Insulin
1.2.7 Interferon (IFN)
1.2.8 Others
1.3 Market by Application
1.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Anti-Cancer
1.3.3 Anti-Inflammatory/Autoimmune
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Perspective (2019-2030)
2.2 Monoclonal antibodies (mAbs) Biosimilars Growth Trends by Region
2.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Region (2019-2024)
2.2.3 Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Region (2025-2030)
2.3 Monoclonal antibodies (mAbs) Biosimilars Market Dynamics
2.3.1 Monoclonal antibodies (mAbs) Biosimilars Industry Trends
2.3.2 Monoclonal antibodies (mAbs) Biosimilars Market Drivers
2.3.3 Monoclonal antibodies (mAbs) Biosimilars Market Challenges
2.3.4 Monoclonal antibodies (mAbs) Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue
3.1.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue (2019-2024)
3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Players (2019-2024)
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
3.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio
3.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2023
3.5 Monoclonal antibodies (mAbs) Biosimilars Key Players Head office and Area Served
3.6 Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
3.7 Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Type (2019-2024)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2025-2030)
5 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Application (2019-2024)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size (2019-2030)
6.2 North America Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2019-2024)
6.4 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size (2019-2030)
7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2019-2024)
7.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size (2019-2030)
8.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2019-2024)
8.4 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size (2019-2030)
9.2 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2019-2024)
9.4 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size (2019-2030)
10.2 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2019-2024)
10.4 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biocon
11.1.1 Biocon Company Detail
11.1.2 Biocon Business Overview
11.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Introduction
11.1.4 Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2019-2024)
11.1.5 Biocon Recent Development
11.2 Celltrion
11.2.1 Celltrion Company Detail
11.2.2 Celltrion Business Overview
11.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Introduction
11.2.4 Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2019-2024)
11.2.5 Celltrion Recent Development
11.3 Dr. Reddy's Laboratories
11.3.1 Dr. Reddy's Laboratories Company Detail
11.3.2 Dr. Reddy's Laboratories Business Overview
11.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Introduction
11.3.4 Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2019-2024)
11.3.5 Dr. Reddy's Laboratories Recent Development
11.4 Hospira
11.4.1 Hospira Company Detail
11.4.2 Hospira Business Overview
11.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Introduction
11.4.4 Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2019-2024)
11.4.5 Hospira Recent Development
11.5 3SBio
11.5.1 3SBio Company Detail
11.5.2 3SBio Business Overview
11.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Introduction
11.5.4 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2019-2024)
11.5.5 3SBio Recent Development
11.6 Accord Healthcare
11.6.1 Accord Healthcare Company Detail
11.6.2 Accord Healthcare Business Overview
11.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Introduction
11.6.4 Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2019-2024)
11.6.5 Accord Healthcare Recent Development
11.7 AET Biotech
11.7.1 AET Biotech Company Detail
11.7.2 AET Biotech Business Overview
11.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
11.7.4 AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2019-2024)
11.7.5 AET Biotech Recent Development
11.8 Allergan
11.8.1 Allergan Company Detail
11.8.2 Allergan Business Overview
11.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Introduction
11.8.4 Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2019-2024)
11.8.5 Allergan Recent Development
11.9 Amega Biotech
11.9.1 Amega Biotech Company Detail
11.9.2 Amega Biotech Business Overview
11.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
11.9.4 Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2019-2024)
11.9.5 Amega Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
*If Applicable.